Latest news with #RocheHoldingAG
Yahoo
15-05-2025
- Business
- Yahoo
Avastin (Bevacizumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2024, 2024-2029F, 2034F
Key player operating in the avastin (bevacizumab) market is Roche Holding AG. North America was the largest region in the avastin (bevacizumab) market in 2024. The regions covered in avastin (bevacizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the avastin (bevacizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Avastin (Bevacizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to Avastin (Bevacizumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the growth during the historical period can be attributed to factors such as regulatory approvals, rising cancer prevalence, clinician adoption, expanding indication approvals, and favorable reimbursement growth during the forecast period is driven by increased awareness, earlier diagnosis, biosimilar competition, the rise of personalized medicine, improved healthcare accessibility, and a growing focus on precision medicine. Key trends for the forecast period include the rise of combination therapies, a shift towards outpatient care, patient-centric treatment models, increased adoption of targeted therapies, and ongoing product increasing prevalence of cancer is expected to drive the growth of the avastin (bevacizumab) market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. The rising incidence of cancer can be attributed to factors such as aging populations, lifestyle changes, and advancements in detection methods. Avastin, a monoclonal antibody, treats cancer by inhibiting VEGF, preventing the formation of blood vessels that supply oxygen and nutrients to tumors, thereby impeding tumor growth. For instance, the American Cancer Society reported that in 2022, approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were anticipated in the United States, equivalent to about 1,670 deaths daily. This rising cancer burden is a significant driver of the avastin market's growth of the Avastin (bevacizumab) market is expected to be propelled by rising healthcare expenditure. Healthcare expenditure encompasses the total spending on health-related goods and services, including personal care, preventive measures, and public health activities, aimed at enhancing health outcomes. This increase is driven by factors such as an aging population, the prevalence of chronic diseases, advancements in medical technology, high drug prices, inefficient payment systems, and a growing demand for healthcare services. Elevated healthcare expenditure facilitates greater access to Avastin through improved insurance coverage, thereby broadening its market reach and patient utilization. For example, a report by the UK's Office for National Statistics in May 2024 highlighted a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, compared to a 0.9% growth rate in 2022. Additionally, long-term health and social care spending rose by 2.8% in real terms in 2022. This trend reflects how increasing investment in healthcare systems supports the accessibility and growth of innovative treatments like Avastin, further driving the market forward.A key trend shaping the avastin (bevacizumab) market is the development of biosimilars to provide cost-effective alternatives and improve access to cancer treatments. Biosimilars, highly similar in structure, function, and efficacy to Avastin, are transforming oncology care by offering affordable options, particularly in resource-constrained settings. For example, in October 2022, Amneal Pharmaceuticals launched ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin, in the U.S. This VEGF inhibitor is indicated for various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, renal cell carcinoma, and gynecologic cancers, demonstrating the potential of biosimilars to enhance treatment (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), effectively inhibiting angiogenesis - the process by which new blood vessels are formed to supply tumors with oxygen and nutrients. It is commonly used in conjunction with chemotherapy to treat various cancers, including colorectal, lung, kidney, and primary dosages of avastin (bevacizumab) are 100 mg and 400 mg. The 100 mg dosage form is used to treat a range of cancers by preventing the growth of blood vessels that nourish tumors. Its applications include non-squamous non-small cell lung cancer, recurrent glioblastoma, cervical cancer, colorectal cancer, ovarian cancer, proliferative diabetic retinopathy, malignant glioma, neurofibromatosis, pancreatic cancer, among others. These products are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, cancer care centers, home healthcare providers, academic and research institutes, and avastin (bevacizumab) market consists of sales of intravenous (iv) formulations, and bevacizumab injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the Topics Covered: 1. Executive Summary2. Avastin (Bevacizumab) Market Characteristics3. Avastin (Bevacizumab) Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Avastin (Bevacizumab) Market Trends and Strategies5. Avastin (Bevacizumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Avastin (Bevacizumab) Growth Analysis and Strategic Analysis Framework6.1. Global Avastin (Bevacizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Avastin (Bevacizumab) Market Growth Rate Analysis6.4. Global Avastin (Bevacizumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Avastin (Bevacizumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Avastin (Bevacizumab) Total Addressable Market (TAM)7. Global Avastin (Bevacizumab) Market Pricing Analysis & Forecasts8. Avastin (Bevacizumab) Market Segmentation8.1. Global Avastin (Bevacizumab) Market, Segmentation by Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 100 Mg 400 Mg 8.2. Global Avastin (Bevacizumab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Non Squamous Non-Small Cell Lung Cancer Recurrent Glioblastoma Cervical Cancer Colorectal Cell Cancer Ovarian Cancer Proliferative Diabetic Retinopathy Malignant Glioma Neurofibromatosis Pancreatic Cancer Other Applications 8.3. Global Avastin (Bevacizumab) Market, Segmentation by Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Direct Tender Hospital Pharmacy Retail Pharmacy Online Pharmacy Other Distribution Channels 8.4. Global Avastin (Bevacizumab) Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hospitals Cancer Supportive Centers Home Healthcare Academic and Research Institutes Other End Users 9. Global Avastin (Bevacizumab) Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Avastin (Bevacizumab) Market Regional and Country Analysis10.1. Global Avastin (Bevacizumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Avastin (Bevacizumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
26-04-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Roche Holding AG (RHHVF – Research Report) and VYNE Therapeutics (VYNE – Research Report) with bullish sentiments. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Roche Holding AG (RHHVF) Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG on April 24 and set a price target of CHF315.00. The company's shares closed last Friday at $318.07. Evans has an average return of 10.6% when recommending Roche Holding AG. According to Evans is ranked #6071 out of 9437 analysts. The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $351.87 average price target, representing a 12.6% upside. In a report issued on April 16, Exane BNP Paribas also initiated coverage with a Buy rating on the stock with a CHF300.00 price target. LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on VYNE Therapeutics yesterday and set a price target of $6.00. The company's shares closed last Friday at $1.43. According to Katkhuda is a 5-star analyst with an average return of 14.5% and a 35.4% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., MoonLake Immunotherapeutics, and Eledon Pharmaceuticals. VYNE Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $6.19, a 324.0% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $4.50 price target.
Bloomberg
24-04-2025
- Business
- Bloomberg
Roche First-Quarter Sales Gain With Pipeline in Focus
Roche Holding AG said sales advanced in the first quarter as investors wait for a series of clinical-trial readouts that will help determine the Swiss drugmaker's future growth. Revenue climbed 7.2% to 15.4 billion Swiss francs ($18.6 billion), Roche said Thursday, compared with an average analyst prediction of 15.3 billion francs.
Bloomberg
22-04-2025
- Business
- Bloomberg
Roche to Invest $50 Billion in Pharma, Diagnostics in US
Roche Holding AG will invest $50 billion in pharmaceuticals and diagnostics in the US in the next five years, as the Swiss drugmaker joins a wave of companies trumpeting American investment in the wake of President Donald Trump's protectionist agenda. The planned investment includes expanded and upgraded manufacturing and distribution capabilities in Kentucky, Indiana, New Jersey, Oregon and California, the health-care firm said in a statement. It will also build a gene therapy manufacturing facility in Pennsylvania, a continuous-glucose monitoring plant in Indiana and a research and development center in Massachusetts, it said.
Boston Globe
09-04-2025
- Business
- Boston Globe
Trump says pharmaceutical tariffs coming ‘very shortly'
Related : 'Once we do that, they're going to come rushing back into our country, because we're the big market,' Trump said. 'The advantage we have over everybody is that we're the big market.' Trump has long bemoaned a lack of domestic pharmaceutical production and has repeatedly promised tariffs to bring more capacity into the country. An index of European health care companies dropped to a two-and-a-half-year low on Wednesday, with shares in AstraZeneca Plc, Novo Nordisk A/S and Roche Holding AG falling around 7 percent before paring losses. A lack of information about the place of manufacturing of drug components makes any assessment of the impact of potential tariffs challenging, analysts John Murphy and Sam Fazeli from Bloomberg Intelligence said in a note. But companies with the lowest gross margins could face the biggest adverse earnings impact, they said, pointing to Bristol-Myers Squibb Co., Pfizer Inc. and Sanofi SA. Advertisement Trump's administration has signaled that they'll use so-called section 232 powers to enact the levies, though they haven't launched the prerequisite investigation. 'We'll be announcing pharmaceuticals at some point in the not too distant future,' Trump said on March 24. 'We don't make pharmaceuticals anymore and if we have problems like wars or anything else, we need steel, we need pharmaceuticals.' Advertisement Trump has already applied 25 percent sectoral tariffs on steel, aluminum and automobiles, while launching the process to also enact them on copper. In addition to pharmaceuticals, his administration has separately pledged additional sectoral levies including on lumber and semiconductor chips, though timing and details are unclear. Trump's sweeping 'reciprocal' tariffs announced last week, which have sapped trillions in value from American markets, exempted sectors that either already have, or may soon have, their own levies. With assistance from Sonja Wind and Hadriana Lowenkron.
